SST2 Quantitative Detection Kit By TRFIA Heart Disease Detection

The incidence of heart failure (HF) increases significantly as people age. The mortality rate within 5 years after the diagnosis of heart failure is up to 50%. Biomarkers play an important role in the diagnosis, curative effect evaluation, and prognosis of heart failure. sST2 can reflect the degree of myocardial fibrosis and predict whether ventricular remodeling will occur. It is worth noting that sST2 is not affected by age, gender, renal function, and other factors. Also, with low reference change values and individuality index values. As a biomarker of vascular health, sST2 usage can be extended to other diseases, including coronary heart disease, myocardial infarction, acute aortic dissection, etc.

A high level of sST2 indicates that the heart is under intense stress. This causes cellular death, tissue fibrosis, decreased heart function, and an increased rate of disease progression. Therefore, sST2 is considered a biomarker of poor prognosis in cardiovascular diseases. It was found that sST2 rising above the normal level increased many negative conditions due to cardiovascular diseases by approximately three times. According to multiple clinical studies, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiovascular diseases, such as myocardial infarction, acute dyspnea, and heart failure, and in the low-risk population.